Literature DB >> 22198845

Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors.

A Kondi-Pafiti1, Evi Kairi-Vassilatou, Ch Iavazzo, Em Vouza, P Mavrigiannaki, Ch Kleanthis, D Vlahodimitropoulos, A Liapis.   

Abstract

AIM: The aim of this study was to investigate the clinicopathological and immunopathological features of Brenner ovarian tumors.
MATERIALS AND METHODS: Thirty cases of Brenner ovarian tumors were examined in our laboratory among 1,680 cases of ovarian tumors, representing 1.5% of all tumors examined. Blocks of paraffin-embedded tumor tissue for all cases were available for additional immunohistochemical stain by a Ventana autoimmunostainer. Moreover, antibodies for Uroplakine III (cellmarque AU-1 clone, 1:25) Chromogen (monosan clone 5H7,1:25) WT1 (novocastra, clone 3F-H2, 1:25) NSE (DAKO, clone BB5/NC/V1-H14, 1:50), CK20 (DAKO, clone Ks20.8, 1:50),CK7 (Zymed 1:25, clone V-TL12/30)were used.
RESULTS: The mean age of the patients was 51.4 years ranging from 16 to 82 years. The tumor was unilateral in 28 cases (16/28 in the right ovary and 12/28 in the left ovary) and bilateral in two cases. Twenty-eight cases (93%) were benign and two (7%) were proliferating (borderline) tumors. Seventeen cases (56%) were pure Brenner tumors, measuring from 0.5 to 2.5 cm and 13 cases (44%) were mixed tumors consisting of a Brenner tumor element and a mucinous ovarian tumor (10/13 cases, 53.8%) and a germ cell tumor in 3/13 cases. The largest diameter of the mixed tumors ranged from 7 to 22 cm. The largest area consisting of Brenner elements measured 7 cm. The immunoprofile of Brenner tumor cell was cytokeratine-7 positive (30/30 cases) cytokeratine-20 negative in the Brenner cell element but positive in the mucinous component in 5/7 cases of mixed Brenner tumors, focally WT-1 positive (5/30 cases), NSE negative (0/30 cases) and focally chromogranine positive (6/30 cases), Uroplakin-III positive in 23/30 cases, with faint cytoplasmatic or luminal distribution. In conclusion, Brenner ovarian tumors are unilateral, small and benign neoplasms in their majority and present specific histopathological and immunopathological characteristics and mixed forms with other epithelial and germ cell neoplasms. This could be explained as a form of metaplasia or a diverse histogenesis from surface epithelium and/or the germ cell ovarian component.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198845     DOI: 10.1007/s00404-011-2182-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

1.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

2.  Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.

Authors:  Laura J Tafe; Kristen E Muller; Guruprasad Ananda; Talia Mitchell; Vanessa Spotlow; Sara E Patterson; Gregory J Tsongalis; Susan M Mockus
Journal:  Am J Pathol       Date:  2016-01-18       Impact factor: 4.307

3.  Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.

Authors:  Rossella De Cecio; Monica Cantile; Francesca Collina; Laura Marra; Clemente Santonastaso; Cono Scaffa; Gerardo Botti; Nunzia Simona Losito
Journal:  J Ovarian Res       Date:  2014-10-29       Impact factor: 4.234

4.  Coexistence of malignant ovarian Brenner tumor and borderline mucinous cystadenoma, combined with primary uterine corpus endometrioid carcinoma: A case report and literature review.

Authors:  Cancan Zou; Qiong Li; Jingbo Zhao; Yanlin Chen
Journal:  Oncol Lett       Date:  2022-06-22       Impact factor: 3.111

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.